Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations

Abstract The phase 3 IMpower150 trial in treatment-naïve patients with metastatic non-small-cell lung cancer (NSCLC) demonstrates significantly longer progression-free (PFS) and overall survival (OS) with first-line atezolizumab (anti-PD-L1)-bevacizumab (anti-VEGF)-carboplatin-paclitaxel (ABCP) than...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tianshi Lu, Habib Hamidi, Mark A. Socinski, Martin Reck, Federico Cappuzzo, Fabrice Barlesi, Robert M. Jotte, Sören Müller, Aditi Qamra, Assaf Amitai, Xiangnan Guan, Eloisa Fuentes, Hartmut Koeppen, Jennifer M. Giltnane, David S. Shames, Marcus Ballinger, Meng Xiao He, Yulei Wang, Minu K. Srivastava, Barzin Y. Nabet
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2025-12-01
coleção:	Nature Communications
Acesso em linha:	https://doi.org/10.1038/s41467-025-66803-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!